Flavio M.N.O. Sidou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Flavio M.N.O. Sidou has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Sifrim
Wingate Institute for Neurogastroenterology, Queen Mary University of London, London, UK
1 shared publication - Genílson José Dias Junior
Federal University of Ceará Fortaleza Brazil
1 shared publication - Humberto Barbosa da Costa Filho
Federal University of Ceará Fortaleza Brazil
1 shared publication - Kerolayne de Melo Nogueira
Postgraduate Program in Pharmacology, Federal University of Ceará - UFC, Fortaleza, Brazil
1 shared publication - Lara Mara Gomes da Silva
Department of Medicine, School of Medicine, Federal University of Ceará, Fortaleza, Brazil
1 shared publication - Lucas Antonio Duarte Nicolau
Universidade Federal do Delta do Parnaíba, Brasil
1 shared publication
Latest Publications
- 12 January 2024
- Published by Wiley in The Laryngoscope
- Vol. 134 (7) , 3080-3085
Pepsin Inhibitors Prevent Inflammation and Loss of Laryngeal Barrier Function in Mice with Gastroesophageal Reflux
Objective: This study aimed to evaluate the role of pepsin inhibitors in the inflammatory response and their effects on laryngeal mucosal integrity during gastroesophageal reflux (GERD) under in vivo conditions.Methods: A surgical model of GERD was used, in which mice were treated with pepstatin (0.3 mg/kg) or darunavir (8.6 mg/kg) for 3 days. On the third day after the experimental protocol, the laryngeal samples were collected to assess the severity of inflammation (wet weight and myeloperoxidase activity) and mucosal integrity (transepithelial electrical resistance and paracellular epithelial permeability to fluorescein).Results: The surgical GERD model was reproduced. It showed features of inflammation and loss of barrier function in the laryngeal mucosa. Pepstatin and darunavir administration suppressed laryngeal inflammation and preserved laryngeal mucosal integrity.Conclusion: Pepsin inhibition by the administration of pepstatin and darunavir improved inflammation and protected the laryngeal mucosa in a mouse experimental model of GERD.Level of Evidence: NA Laryngoscope, 134:3080–3085, 2024
- 12 January 2024
- Published by Wiley in The Laryngoscope
- Vol. 134 (7) , 3080-3085
Pepsin Inhibitors Prevent Inflammation and Loss of Laryngeal Barrier Function in Mice with Gastroesophageal Reflux
Objective: This study aimed to evaluate the role of pepsin inhibitors in the inflammatory response and their effects on laryngeal mucosal integrity during gastroesophageal reflux (GERD) under in vivo conditions.Methods: A surgical model of GERD was used, in which mice were treated with pepstatin (0.3 mg/kg) or darunavir (8.6 mg/kg) for 3 days. On the third day after the experimental protocol, the laryngeal samples were collected to assess the severity of inflammation (wet weight and myeloperoxidase activity) and mucosal integrity (transepithelial electrical resistance and paracellular epithelial permeability to fluorescein).Results: The surgical GERD model was reproduced. It showed features of inflammation and loss of barrier function in the laryngeal mucosa. Pepstatin and darunavir administration suppressed laryngeal inflammation and preserved laryngeal mucosal integrity.Conclusion: Pepsin inhibition by the administration of pepstatin and darunavir improved inflammation and protected the laryngeal mucosa in a mouse experimental model of GERD.Level of Evidence: NA Laryngoscope, 134:3080–3085, 2024